MedTrace Logo

A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer

NCT03899649 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 532

Last updated 2025-02-12

No results posted yet for this study

Summary

This multicenter, observational study will evaluate the effectiveness and safety of the NanoKnife System when used for the ablation of Stage 3 pancreatic adenocarcinoma (Stage 3 PC). Eligible patients will be recruited over a 36-month period and participating institutions will enroll and provide data on consecutive patients that meet inclusion and exclusion criteria. Each patient will be followed up for the duration of the study or until death. The study will include two (2) cohorts: patients who received standard of care (SOC) and received irreversible electroporation (IRE) \[IRE cohort\], and patients who were treated with SOC and did not receive IRE \[SOC cohort\].

Conditions

  • Stage III Pancreatic Cancer

Interventions

DRUG

SOC

Standard of Care treatment

DEVICE

NanoKnife System

Irreversible Electroporation

Sponsors & Collaborators

  • Angiodynamics, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-08
Primary Completion
2025-04-30
Completion
2025-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03899649 on ClinicalTrials.gov